Neogenix Oncology, Inc.'s Novel Antibody NEO-101 Named One of Windhover Information Inc.'s Top 10 Projects to Watch  
11/30/2011 8:55:38 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--Neogenix Oncology, Inc. has announced that the company’s novel antibody NEO-101, which targets pancreatic and colorectal cancer cells, has been selected as one of Windhover’s 2011 Top 10 Projects to Watch.